↓ Skip to main content

Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in…

Overview of attention for article published in European Urology Oncology, August 2019
Altmetric Badge

Mentioned by

twitter
8 X users
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
Published in
European Urology Oncology, August 2019
DOI 10.1016/j.euo.2019.07.014
Pubmed ID
Authors

Joaquim Bellmunt, Emilio Esteban, Xabier García Del Muro, Juan Manuel Sepúlveda, Pablo Maroto, Enrique Gallardo, Aranzazu González Del Alba, Olatz Etxaniz, Marta Guix, Jose Luis González Larriba, Jose A Arranz, Miriam Redrado, Alfonso Calvo

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 4 18%
Researcher 3 14%
Student > Master 2 9%
Student > Ph. D. Student 2 9%
Librarian 1 5%
Other 3 14%
Unknown 7 32%
Readers by discipline Count As %
Medicine and Dentistry 7 32%
Pharmacology, Toxicology and Pharmaceutical Science 4 18%
Biochemistry, Genetics and Molecular Biology 3 14%
Unspecified 1 5%
Unknown 7 32%